Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

NCT06272487 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

High Cardiovascular Risk
Hypertension

Interventions

DRUG: Zilebesiran
DRUG: Placebo

Sponsor

Alnylam Pharmaceuticals